Objective-We studied the expression and function of an mRNA-binding protein, zinc finger protein-36 (ZFP36), in vascular endothelial cells in vivo and in vitro. We tested the hypotheses that ZFP36 regulates inflammation in vascular endothelial cells and that it functions through direct binding to target cytokine mRNAs. We also tested whether ZFP36 inhibits nuclear factor-κB-mediated transcriptional responses in vascular endothelial cells. Approach and Results-ZFP36 was minimally expressed in healthy aorta but was expressed in endothelial cells overlying atherosclerotic lesions in mice and humans. The protein was also expressed in macrophage foam cells of atherosclerosis. ZFP36 was expressed in human aortic endothelial cells in response to bacterial lipopolysaccharide, glucocorticoid, and forskolin, but not oxidized low-density lipoproteins or angiotensin II. Functional studies demonstrated that ZFP36 reduces the expression of inflammatory cytokines in target cells by 2 distinct mechanisms: ZFP36 inhibits nuclear factor-κB transcriptional activation and also binds to cytokine mRNAs, leading to reduced transcript stability.
A therosclerosis is an inflammatory disease, and cardiovascular disease remains the leading cause of death in the United States. Initial accumulation of lipoproteins in the subendothelial space leads to an inflammatory response in overlying endothelial cells and subsequent recruitment of monocyte/macrophage cells to the subendothelial compartment. 1 Activated endothelial cells secrete and respond to a variety of inflammatory signaling molecules, including monocyte chemoattractant protein-1 (MCP-1/CCL2), interleukin-6 (IL-6), and interferon-γ. The resulting recruitment of immune cells leads to the initiation and establishment of atherosclerotic lesions. 2 The chemokine MCP-1 is expressed in vascular endothelial cells, vascular smooth muscle cells, and macrophages of atherosclerotic lesions. 3 In mouse models, genetic deletion of MCP-1 or its receptor CCR2 results in protection from atherosclerosis. [4] [5] [6] In humans, inflammation engendered by IL-6 correlates with the risk for coronary artery disease, and direct effects of IL-6 on atherogenesis have been demonstrated in mouse models of the disease. [7] [8] [9] An essential means of regulating cytokine gene expression occurs at the level of mRNA stability. 10 Much of this regulation occurs by the binding and stabilizing, or destabilizing, of target mRNAs by proteins that recognize AU-rich elements (AREs, core sequence 5′-AUUUA) located in the untranslated regions of these transcripts. 11 Zinc finger protein-36 (ZFP36) is an ARE-binding protein (ARE-BP) that destabilizes target mRNAs leading to message destruction and diminished protein expression. 12, 13 There are 3 members of the human ZFP36 family (ZFP36, ZFP36L1, and ZPF36L2), which share tandem zinc finger domains that bind to AREs of target transcripts. 12 These proteins are expressed in a variety of cell types, including monocytes and macrophages, and their targets include tumor necrosis factor-α (TNFα/TNFA), granulocyte macrophage colony-stimulating factor, IL-3, IL-8, vascular endothelial growth factor, and cyclooxygenase-2. 12, 14 ZFP36 null mice demonstrate cachexia, arthritis, and autoimmunity that is reversible when systemic TNFα is neutralized, indicating that ZFP36 subserves important and nonredundant functions. 15, 16 Recently, ZFP36 was demonstrated to interact with the p65 subunit of nuclear factor-κB (NF-κB), leading to decreased nuclear import and diminished transcriptional activation mediated by NF-κB. 17, 18 These data suggest 2 important mechanisms by which ZFP36 might suppress inflammatory responses: by regulating NF-κB-mediated transcriptional responses and by regulating cytokine mRNA stability.
While studying the expression of ZFP36 in the fat depots of obese mice, 19 we observed that ZFP36 is expressed in the vascular endothelium of mice with atherosclerosis but not in the vascular endothelium of normal mice. Little is known about the function of ZFP36 in endothelial cells, although a recent report demonstrated that hypoxia inducible factor-1α is regulated by ZFP36 in an immortalized endothelial cell line. 20 In this report, we have studied the expression and function of ZFP36 in vascular endothelial cells in vivo and in vitro. We hypothesized that enhancing vascular endothelial cell expression of ZFP36 would attenuate inflammatory cytokine/chemokine expression in these cells. We reasoned that the anti-inflammatory effects of endothelial cell ZFP36 might identify ZFP36 as a potential therapeutic target for the prevention or treatment of atherosclerosis.
Materials and Methods
Materials and Methods are provided in the online-only Supplement.
Results

Characterization of Rabbit Anti-ZFP36 Antiserum
Full-length human ZFP36 protein was purified and used to generate rabbit antiserum. Figure 1A shows that the resulting antiserum detected both mouse and human ZFP36 proteins (which share ≈84% amino acid identity) by Western blot. To test the antiserum for its ability to detect mouse ZFP36, we used murine RAW 264.7 monocyte/macrophage cells, wherein 4 hours of lipopolysaccharide (LPS) treatment potently induces endogenous ZFP36 expression ( Figure  1A ). 13 Because ZFP36 protein is variably phosphorylated at multiple residues, the protein migrates as a broad-staining band of ≈37 to 44 kDa apparent molecular weight. 13, [21] [22] [23] We engineered human 293T cells transfected with either empty vector or human ZFP36 expression vector to confirm that our antiserum detects human ZFP36 protein ( Figure 1A ). Comparison of our antihuman ZFP36 antiserum and an antimouse ZFP36 antiserum 24 is shown in Figure II in the online-only Data Supplement. Specificity of our antiserum against ZFP36 was also demonstrated using shRNA-mediated knockdown of ZFP36 expression in human aortic endothelial cells (HAEC; see Figure III in the online-only Data Supplement).
Control and ZFP36 overexpressing 293T cell lysates were next subjected to immunoprecipitation (IP) using the antihuman ZFP36 antiserum, followed by Western blot of the immunoprecipitates using the same antiserum (ie, IP-Western). Our antiserum effectively immunoprecipitated ZFP36 protein by IP-Western ( Figure 1B ) confirming the use of this antiserum in subsequent RNA immunoprecipitation-polymerase chain reaction studies (see below).
ZFP36 Is Expressed in Atherosclerosis
We recently demonstrated the anti-inflammatory effects of ZFP36 in adipocytes, 19 and we hypothesized that ZFP36 might play a role in reducing inflammation in atherosclerosis. Immunofluorescent microscopy was performed to assess ZFP36 expression patterns in vivo. Wild-type C57BL/6 mice fed regular chow did not develop atherosclerosis and demonstrated low ZFP36 expression (red) in the aorta (Figure 2A , with 4′-6-diamidino-2-phenylindole-stained nuclei in blue). By contrast, C57BL/6 mice on the apoE −/− background developed substantial atherosclerosis when fed a high-calorie/ high-fat Western diet for 6 weeks: these mice demonstrated significant expression of ZFP36 (red) in the macrophageladen lesions of the aortic neointima ( Figure 2B ; a 10× magnification and Figure 2C ; a 20× magnification). Interestingly, ZFP36 expression was also high in the vascular endothelial cells overlying atherosclerotic lesions ( Figure 2B and 2C) but not in healthy endothelium (Figure 2A ).
ZFP36 expression was next assessed in human coronary arteries from subjects with stage 2 atherosclerosis. Hematoxylin and eosin staining revealed neointimal expansion and macrophage foam cell accumulation in the neointima ( Figure 2D ). Staining of the same lesion with preimmune serum revealed minimal background immunofluorescence (Figure 2E , red). Using fluorescent microscopy of human coronary artery atherosclerosis with 4′-6-diamidino-2-phenylindole-stained nuclei ( Figure 2F , 4′-6-diamidino-2-phenylindole alone), we observed strong expression of ZFP36 in neointimal cells and endothelial cells ( Figure 2G , green). Using dual immunofluorescence confocal microscopy ( Figure 2G and 2I), we confirmed colocalization of ZFP36 and CD68 expression in the monocyte/macrophage cells of the neointima but not in ZFP36-expressing vascular endothelial cells. Similar findings were observed when staining with an antihuman ZFP36 peptide antibody that was obtained commercially (Sigma-T5242, see Figure IV in the online-only Data Supplement). These data demonstrate enhanced ZFP36 expression in activated macrophages and endothelial cells of atherosclerotic lesions in mice and humans.
ZFP36 Is Expressed in Primary HAEC
To study the functions of ZFP36 in vascular cells, we first tested for endogenous ZFP36 expression in primary HAEC. ZFP36 expression was low in unstimulated HAEC, consistent with its role as an acute phase reactant in other cell types ( Figure 3A ). As previously observed in adipocytes, 19 treatment of HAEC with bacterial LPS (500 ng/mL) for 4 hours resulted in enhanced expression of ZFP36 in HAEC ( Figure 3A ). The glucocorticoid dexamethasone (1 μmol/L) and the activator of adenylate cyclase, forskolin (10 μmol/L), which generates intracellular cAMP, both enhanced ZFP36 expression in primary HAEC ( Figure 3A ). Positive control 293T cells engineered to overexpress ZFP36 are also shown ( Figure 3A) .
These data confirmed vascular endothelial cell expression of ZFP36 in response to inflammatory and endocrine stimuli previously demonstrated to enhance ZFP36 expression in other cell systems. 13, 19 These treatments in our model system serve to recapitulate classic inflammatory (LPS) and antiinflammatory (dexamethasone, cAMP) stimuli relevant to the pathogenesis of atherosclerosis (see Discussion). Recent data indicate that the glucocorticoid receptor directly regulates ZFP36 expression in pulmonary epithelial cells. 25 We tested oxidized low-density lipoproteins (Ox-LDL) for their well recognized ability to trigger atherosclerosis in part by activating toll-like receptor 4 (TLR4) receptors that are targeted by LPS. We did not observe any effects of Ox-LDL on ZFP36 expression in HAEC ( Figure VI in the onlineonly Data Supplement). Similarly, although angiotensin II is recognized as a proinflammatory molecule important to the pathogenesis of atherosclerosis, we did not observe an effect of angiotensin II treatment on ZFP36 expression in HAEC ( Figure VI in the online-only Data Supplement). 26 Because our laboratory has observed cell-type-specific stimuli regulating ZFP36 in adipocytes compared with macrophages, 19 we also tested a macrophage-like cell line (THP-1) for responsiveness to Ox-LDL. THP-1 macrophages accumulate Ox-LDLs in a process that recapitulates in vivo macrophage foam cell behavior. 27 As observed for primary HAEC, LPS was a potent stimulator of ZFP36 expression in THP-1 macrophages, whereas Ox-LDL did not regulate ZFP36 in these cells under our culture conditions ( Figure VI in the online-only Data Supplement).
The observation that LPS, dexamethasone, and intracellular cAMP each enhances ZFP36 expression in HAEC indicates that several distinct pathways and second messenger systems are conserved in diverse cell types to regulate the expression of ZFP36. 13, 19 These data supported the use of isolated primary HAEC for further studies regarding ZFP36 function.
ZFP36 Reduces Expression of Inflammatory Transcripts in HAEC
We recently demonstrated that the net effect of ZFP36 in adipocytes is anti-inflammatory. 19 This observation is consistent with the phenotype of ZFP36 null mice which are chronically inflamed and cachectic. 15, 16 We tested whether elevating expression of ZFP36 in primary HAEC would reduce expression of mRNAs for inflammatory factors. First, we confirmed that lentiviral expression systems could be used to overexpress ZFP36 in primary HAEC ( Figure 3B ). Next, using empty vector or ZFP36-expressing lentiviral particles, we generated lowand high-ZFP36-expressing HAEC lines, respectively, and measured mRNA levels of MCP-1 and IL-6. High expression of ZFP36 potently repressed mRNA expression of MCP-1 and IL-6 in primary HAEC ( Figure 4A ). By contrast, ZFP36 overexpression had no significant effect on expression of histone cluster 1, H2ac mRNAs that lack AU-rich elements. These data indicate that ZFP36 represses the expression of MCP-1 and IL-6 transcripts in primary human endothelial cells.
ZFP36 Reduces Expression of Inflammatory Proteins in HAEC
We next tested whether ZFP36-dependent mRNA expression changes correlated with protein expression changes for inflammatory factors. We measured the levels of MCP-1 and IL-6 secreted into the media of low-and high-ZFP36expressing HAEC generated using lentiviral particles (above). Cells were placed in serum-free culture medium for 24 hours before treatment with vehicle control or LPS (500 ng/mL) for an additional 24 hours. Conditioned media was then tested by ELISA, and data were normalized to total protein in each well. High-ZFP36 expression significantly reduced the expression of MCP-1 and IL-6 proteins in both basal and LPS-stimulated cells ( Figure 5 ).
ZFP36 Reduces Activation of Nuclear NF-κB in HAEC
ZFP36 represses mRNA expression of inflammatory factors by at least 2 mechanisms: direct binding to AREs in target mRNAs leading to transcript destruction 12 and binding to NF-κB leading to decreased nuclear import and diminished NF-κB-mediated transcriptional activation of cytokine/ chemokine genes. 17, 18 Interestingly, both transcriptional and posttranscriptional activities of ZFP36 have been shown to modulate the expression of TNFα and IL-8. 17, 28, 29 The mechanisms by which ZFP36 regulates IL-6 and MCP-1 mRNA expression are not known. Although IL-6 transcripts have 6 minimal pentamer ARE elements (AUUUA) in the 3′-untranslated region of their mRNAs, MCP-1 transcripts have only 2 AREs. Both genes are known transcriptional targets of NF-κB. 30, 31 We tested low-and high-ZFP36-expressing HAEC for activation of nuclear NF-κB after 30-minute stimulation with LPS. Although LPS produced ≈2-fold activation of NF-κB in low-ZFP36-expressing cells, this effect was blocked by overexpression of ZFP36 ( Figure 4B ). These data indicate that the anti-inflammatory effects of ZFP36 in HAEC occur partly by inhibiting NF-κB-mediated transcriptional responses.
ZFP36 Binds IL-6 and MCP-1 Transcripts
We next tested the extent to which ZFP36 binds to target transcripts to regulate mRNA expression. We used RAW 264.7 cells because these cells propagate robustly and maintain their phenotype even after many passages, whereas primary HAEC lose their phenotype after several passages. Further, RAW 264.7 cells express high levels of ZFP36 and high levels of inflammatory factors when stimulated with LPS, facilitating their use in RNA immunoprecipitation-polymerase chain reaction assays.
We first confirmed that the RNA immunoprecipitationpolymerase chain reaction assay is able to detect the previously established interaction of ZFP36 with TNFα transcripts ( Figure 6 ). We then demonstrated that ZFP36 binds directly to IL-6 and MCP-1 transcripts, but not to histone cluster 1, H2ac transcripts that lack ARE elements ( Figure 6 ). In the basal state, where ZFP36 and cytokine expression remain low, there was a nonsignificant trend toward enrichment of TNFα and MCP-1 transcripts bound to ZFP36 compared with control (preimmune serum). In LPS-stimulated cells, which express high levels of inflammatory mRNAs and high levels of endogenous ZFP36, there was significant enrichment of TNFα, IL-6, and MCP-1 transcripts bound to ZFP36. We observed no enrichment for histone cluster 1, H2ac mRNA using ZFP36 antiserum in basal or LPS-stimulated cells, consistent with the fact that histone cluster 1, H2ac transcripts lack binding sites for ZFP36 ( Figure 6 ). These data establish for the first time that ZFP36 interacts with IL-6 and MCP-1 mRNA.
Discussion
Healthy arterial endothelium plays important roles in maintaining vessel wall function by regulating vessel tone and limiting leukocyte adhesion, thrombus formation, and proliferation of vascular smooth muscle cells. Established triggers of atherosclerosis include the accumulation of Ox-LDL in the vascular intima and insult by bacterial pathogens or tissue injury, each leading to endothelial cell dysfunction and activation. 32 Responding to innate immune system signals, endothelial cells then produce cell surface adhesion molecules, inflammatory cytokines, and chemokines, which contribute to the initiation and progression of atherosclerotic lesions. 33 This article reports ZFP36 expression in vascular endothelial cells of atherosclerotic lesions in vivo and in primary HAEC in vitro. Our interest in developing new targets with which to decrease the inflammation associated with obesity prompted our studies of ZFP36 in adipose tissues, 19 leading to our observation that ZFP36 is also expressed in atherosclerosis. Interestingly, both obesity and atherosclerosis share the pathogenic processes of lipid accumulation, inflammatory cell infiltration, cytokine production, and disruption of vascular endothelial cell functions.
ZFP36 regulates mRNA expression both transcriptionally 17,18 and posttranscriptionally. 12 We studied the effects of enhanced expression of ZFP36 on IL-6 and MCP-1 production in cultured aortic endothelial cells. Enhanced expression of ZFP36 reduced the mRNA and protein expression of IL-6 and MCP-1 ( Figures  4 and 5 ). We went on to demonstrate that ZFP36 reduces NF-κB activity in HAEC, indicating an indirect transcriptional response to ZFP36 expression ( Figure 4B ). Our gene expression data combined with the RNA immunoprecipitationpolymerase chain reaction data demonstrated that ZFP36 also regulates MCP-1 and IL-6 mRNA stability via direct binding to these transcripts ( Figures 4A and 6 ). Our positive control for these assays confirmed TNFα transcripts to be direct targets of ZFP36 ( Figure 6 ). 21 Together, our data indicate that ZFP36 reduces inflammatory gene expression in HAEC both transcriptionally and posttranscriptionally. Studies are underway to quantify the relative contribution of transcriptional versus posttranscriptional effects of ZFP36 with respect to cytokine expression in HAEC. Because cytokine and noncytokine mRNAs may be subject to ARE-BP-mediated regulation, unbiased approaches are underway to comprehensively determine the global gene expression changes engendered by ZFP36 in endothelial cells.
Human and mouse MCP-1 transcripts have 1 and 2 core ARE elements, respectively. Because AREs often occur in multiple copies in transcripts that are regulated by ARE-BPs, the low copy number of AREs in the MCP-1 transcripts was suspected to be insufficient for ZFP36 binding. 17 Our data indicate that ZPF36 binds MCP-1 mRNA and that exogenous ZFP36 represses MCP-1 protein expression (Figures 4 and 6) . These data are consistent with a recent report in which an alternative ARE-BP, Hu antigen R, was shown to bind to MCP-1 transcripts in human airway epithelial cells. 34 Thus, it is likely that MCP-1 expression is regulated, at least in part, by ARE-BPs functioning at the posttranscriptional level in a variety of cell types. Whether protein intermediaries facilitate ZFP36 binding to MCP-1 transcripts, and whether atypical ARE sequences reside in MCP-1 transcripts, remains to be explored.
We have identified proinflammatory (LPS) and antiinflammatory (dexamethasone, cAMP) factors that enhance ZFP36 expression in primary HAEC (Figure 3 ). Prior work has identified several transcription factors that regulate ZFP36 gene expression in diverse cell types: activator protein 2, 35 NF-κB 36 glucocorticoid receptor, early growth response 1, specificity protein 1, TTP promoter element 1, signal transducer and activator of transcription 3. 37 Given the data implicating NF-κB (which is activated by cAMP via protein kinase A and also via LPS-stimulated TLR4) 38 and GR in the transcriptional regulation of the ZFP36 promoter, our data demonstrating ZFP36 responsiveness to LPS, cAMP, and dexamethasone exposure are consistent with these pathways regulating ZFP36 expression in HAEC. The magnitude of the ZFP36 response to each ligand was not uniform and suggests complex metabolic or gene regulatory pathways that remain Figure 6 . Zinc finger protein-36 (ZFP36) directly binds to inflammatory mRNA transcripts. RAW cells±lipopolysaccharide (LPS) stimulation were subjected to ribonucleoprotein immunoprecipitation (using preimmune or ZFP36 antiserum) followed by quantitative reverse transcriptase polymerase chain reaction. ZFP36 bound directly to tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) but not histone cluster 1, H2ac (H2A) transcripts. Mean values with SEM for 3 independent experiments normalized to preimmune control (*P<0.05).
to be studied in HAEC (including ligand receptor levels, coregulatory protein levels, and counter-regulatory pathways).
There is an emerging appreciation that cAMP produces anti-inflammatory effects in vascular endothelial cells in response to inflammatory stimuli, including vascular endothelial growth factor, adrenomedullin, prostacyclin, prostaglandin E2, β-adrenergic agonists, 39 and shear stress. cAMP acts via multiple signaling pathways, including PKA, and may play a role in the pathogenesis of atherosclerosis. [40] [41] [42] To this end, ours is the first report implicating the mRNA-binding protein ZFP36 in the anti-inflammatory response to cAMP in vascular endothelial cells. In addition to enhancing ZFP36 gene expression in HAEC, it is noteworthy that ZFP36 is also a target of PKA kinase activity. 43 More than 6 kinases seem to phosphorylate at least 12 Ser/Thr residues of ZFP36, with ongoing studies addressing the net functional effects of ZFP36 phosphorylation (effects which may modulate ZFP36 localization, half-life, and protein:protein interactions). 44 Endotoxemia (elevated serum LPS) has recently been linked to high-fat diets and has been associated with increased risk of diabetes mellitus and atherosclerosis. [45] [46] [47] [48] [49] [50] The receptors for LPS include innate immune TLR4 receptors for which there is considerable data that both endotoxin (ie, LPS) and modified LDLs may serve as activators which promote atherogenesis in the setting of high-fat diet, bacterial infection, periodontal disease, alcohol consumption, and cigarettes (recently reviewed 51 ) and which may be mitigated in TLR4deficient mice and in mice treated with TLR4 antagonists. 52 We observed that acute (4 hours) exposure of HAEC to Ox-LDL and angiotensin II, traditional molecules associated with atherogenesis, did not modulate ZFP36 expression in these cells. Meanwhile, acute exposure to LPS promoted ZFP36 expression in these cells, consistent with the proposed role of chronic infection as a stimulus for the development of atherosclerosis in some settings (and consistent with our hypothesis that ZFP36 acts to repress inflammation engendered by some inflammatory stimuli, see below). 32 Additional studies will be required to test which atherogenic molecules regulate ZFP36 expression in vivo.
This work establishes that ZPF36 is expressed in activated macrophages and endothelial cells of atherosclerotic lesions in mice and humans ( Figure 2 ). The authors surveyed apoE null mouse aortas with modest and moderate amounts of atherosclerosis and observed no significant differences when comparing ZFP36 staining of the athero-prone inner arch to the athero-resistant outer arch (not shown). These data indicate that ZFP36 expression is probably not regulated by hemodynamics and is not expressed before the development of systemic inflammation.
Our observations are consistent with a model in which inflammation is tightly regulated by compensatory increases in anti-inflammatory proteins, such as ZFP36. 21, 53 A negative feedback loop in which inflammatory factors enhance expression of the anti-inflammatory ZFP36 is analogous to regulation observed in other immune processes: TLR signaling in macrophages is followed by inactivation of MyD88 leading to inhibition of further TLR signaling, 54 T-cell receptor signaling leads to activation of proteins (ie, NFKBIB and the RCAN family), which ultimately terminate the T-cell response, 55 and many inflammatory stimuli also induce expression of suppressor of cytokine signaling proteins which feedback to inhibit additional cytokine signaling. 56 Future studies will identify in vivo (and possibly cell-type specific) regulators of endothelial cell ZFP36 expression with a view to developing new therapies for the prevention of atherosclerosis.
Our data suggest a role for ZFP36 in responding to inflammatory stimuli to reduce cytokine/chemokine expression in both adipocytes and vascular endothelial cells. Interestingly, recent SNP analysis revealed ZFP36 to be a candidate gene for influencing the metabolic syndrome in humans. 57 Additional work suggested that high-ZFP36 expression in adipose tissue may offer protection against the development of insulin resistance and the metabolic syndrome. 58 In light of these observational studies linking ZFP36 to the metabolic syndrome, which is a risk factor for atherosclerosis, a broader role for adipocyte-and endothelial cell-expressed ZFP36 in modulating inflammatory responses warrants investigation.
In this report, we have shown that forced expression of ZFP36 reduces basal and LPS-stimulated IL-6 and MCP-1 expression in vascular endothelial cells. Further, we have demonstrated 2 mechanisms of ZFP36-mediated inhibition of these transcripts: transcriptional and posttranscriptional. Studies to characterize additional cytokine and noncytokine mRNA targets of vascular endothelial cell ZFP36 are ongoing. The targeted manipulation of mRNA-binding proteins, such as ZFP36, represents a novel candidate approach to reducing inflammation and may prove beneficial in preventing or treating inflammatory disorders, such as atherosclerosis.
